Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Aug 16, 2018 at 9:55 AM EDT

Why Summit Therapeutics Is One of Thursday’s Top Biotechs

Summit Therapeutics shares made a solid gain early on Thursday after the firm announced that it was awarded an additional…

Jon C. Ogg | Aug 15, 2018 at 11:50 AM EDT

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors.…

Chris Lange | Aug 15, 2018 at 9:35 AM EDT

What the FDA Has to Say About Regeneron’s Eylea

Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients…

Douglas A. McIntyre | Aug 14, 2018 at 6:25 AM EDT

Google Bests Doctors in Eye Disease Treatment

In another sign that artificial intelligence can outthink humans, Google announced it was able to more quickly detect eye disease…

Chris Lange | Aug 10, 2018 at 9:50 AM EDT

Short Sellers Hike Bets in Major Pharma Stocks

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 10, 2018 at 8:45 AM EDT

Why Have Short Sellers Backed Off Major Biotechs?

The July 31 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Aug 8, 2018 at 1:40 PM EDT

Why Boston Scientific Could Retest All-Time Highs

Boston Scientific announced early Wednesday morning that it will be in position to submit the final Lotus Edge Premarket Approval…

Chris Lange | Aug 8, 2018 at 12:40 PM EDT

What Analysts Are Saying After Spark Therapeutics Q2 Report

Spark Therapeutics took a massive hit on Tuesday that wiped out about 28% of the share price in the wake…

Chris Lange | Aug 8, 2018 at 11:35 AM EDT

Why Mylan Is Paying the Price for Q2

Mylan reported disappointing quarterly results before the markets opened on Wednesday, and shares retreated afterward.

Jon C. Ogg | Aug 7, 2018 at 1:25 PM EDT

Ready or Not, Health Care Costs Projected to Rise Another 5% in 2019

Whether you are a consumer or an employer, there is a pretty good chance you would like to have lower…

Chris Lange | Aug 7, 2018 at 11:20 AM EDT

Why Gemphire Is Tuesday’s Big Biotech Loser

Gemphire shares were more than halved on Tuesday after the company provided an update in regards to the clinical hold…

Chris Lange | Aug 6, 2018 at 12:10 PM EDT

Why Ovid Therapeutics Is Monday’s Big Biotech Loser

Ovid Therapeutics shares were crushed to start the week even though the company announced positive midstage results for its Angelman…

Chris Lange | Aug 6, 2018 at 11:00 AM EDT

Why Protagonist Therapeutics Is Getting a Second Chance

Protagonist Therapeutics shares saw a solid gain on Monday after the firm announced positive results from its midstage trial in…

Chris Lange | Aug 3, 2018 at 10:40 AM EDT

Eli Lilly to Spin Off Elanco in IPO

Animal health company Elanco Animal Health has filed with the SEC regarding its initial public offering.

Chris Lange | Aug 2, 2018 at 9:40 AM EDT

Teva Just Can’t Seem to Get Earnings Right

Teva shares stumbled after it released its most recent quarterly results before the markets opened on Thursday.

1 … 123 124 125 126 127 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Summit Therapeutics Is One of Thursday’s Top Biotechs

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

What the FDA Has to Say About Regeneron’s Eylea

Google Bests Doctors in Eye Disease Treatment

Short Sellers Hike Bets in Major Pharma Stocks

Why Have Short Sellers Backed Off Major Biotechs?

Why Boston Scientific Could Retest All-Time Highs

What Analysts Are Saying After Spark Therapeutics Q2 Report

Why Mylan Is Paying the Price for Q2

Ready or Not, Health Care Costs Projected to Rise Another 5% in 2019

Why Gemphire Is Tuesday’s Big Biotech Loser

Why Ovid Therapeutics Is Monday’s Big Biotech Loser

Why Protagonist Therapeutics Is Getting a Second Chance

Eli Lilly to Spin Off Elanco in IPO

Teva Just Can’t Seem to Get Earnings Right

Buy Any Month, Always Hedged: The ETF Built for Investors Who Bail at Every Dip

Price Prediction: Tesla Poised for 12% Rally as Profit Margins Improve

She Claimed Social Security at 62 and Kept Working. The Earnings Limit Took Back $1 of Every $2.

She Claimed Social Security at 62 and Kept Working. The Earnings Limit Took Back $1 of Every $2.

They've Wanted to Downsize for Years, but a 3% Mortgage Trapped Them. As the Market Thaws, This Couple Faces a Fixed-Income Dilemma.

Buy Any Month, Always Hedged: The ETF Built for Investors Who Bail at Every Dip

Price Prediction: Tesla Poised for 12% Rally as Profit Margins Improve

Health and Healthcare Articles

All Health and Healthcare Articles

Why Summit Therapeutics Is One of Thursday’s Top Biotechs

Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

What the FDA Has to Say About Regeneron’s Eylea

Google Bests Doctors in Eye Disease Treatment

Short Sellers Hike Bets in Major Pharma Stocks

Why Have Short Sellers Backed Off Major Biotechs?

Why Boston Scientific Could Retest All-Time Highs

What Analysts Are Saying After Spark Therapeutics Q2 Report

Why Mylan Is Paying the Price for Q2

Ready or Not, Health Care Costs Projected to Rise Another 5% in 2019

Why Gemphire Is Tuesday’s Big Biotech Loser

Why Ovid Therapeutics Is Monday’s Big Biotech Loser

Why Protagonist Therapeutics Is Getting a Second Chance

Eli Lilly to Spin Off Elanco in IPO

Teva Just Can’t Seem to Get Earnings Right

Buy Any Month, Always Hedged: The ETF Built for Investors Who Bail at Every Dip

Price Prediction: Tesla Poised for 12% Rally as Profit Margins Improve

She Claimed Social Security at 62 and Kept Working. The Earnings Limit Took Back $1 of Every $2.

Featured Reads

She Claimed Social Security at 62 and Kept Working. The Earnings Limit Took Back $1 of Every $2.

They've Wanted to Downsize for Years, but a 3% Mortgage Trapped Them. As the Market Thaws, This Couple Faces a Fixed-Income Dilemma.